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Abstract
Parkinson’s disease has become a growing issue worldwide and has yet to be presented with a
cure. Various treatment methods have been introduced that include physical exercise, genetic
therapy, pharmacological treatment, and/or alternative methods. An extended literature review
was conducted evaluating numerous articles and focus was given to an ongoing research project
in an effort to present current information. As a result, various routes of effective treatment have
been evaluated for treating Parkinson’s diseases by observing if symptoms or the
progression/prevention of the disease is hindered/reduced. Thus, a summary is given concerning
what methods are effective in treating the disease. Regarding the future, suggestions are given
considering what can be done to improve current methods and what other opportunities may be
available. In all, this thesis presents a discussion of Parkinson’s disease in terms of its history,
current methods of treatment, and future studies.

KEY WORDS: Parkinson’s disease, Rock Steady, levodopa, physical exercise, DOPAL

iv

Table of Contents
Introduction………………………………………………………………………………………1
Review of Literature....…………………………………………………………………………...4
Physical Exercise as a Method for Treatment……………………………………………4
Genetics as a Method for Treatment……………………………………………………...9
Pharmacological Therapies as a Method for Treatment…………………………………14
Alternative Therapies as a Method for Treatment……………………………………….20
Methodology……………………………………………………………………………………..22
Analysis of Data....……………………………………………………………………………….23
Therapeutic Analysis…………………………………………………………………….23
Future Methods…………………………………………………………………………..27
Conclusion……………………………………………………………………………………….29
References………………………………………………………………………………………..30

Running head: THE TREATMENT OF PARKINSON’S DISEASE

1

Introduction
From an international perspective, health and quality of life are a common goal that all
countries share, as demonstrated by the progress made within the past century towards increasing
life expectancy (Senior Living, 2017). However, there are various health issues that still exist
that have yet to be cured. One primary example that needs to be addressed is Parkinson’s disease,
which is the second most common neurodegenerative disease in the United States (Earhart &
Williams, 2012). Based on the U.S. 2010 census, approximately 680,000 people at the age of 45
and older suffer from this disease (Marras et al., 2018). Overall, it is estimated by 2020, this
number will rise to 930,000, and by 2030, to 1,238,000 (Marras et al., 2018). Therefore, society
needs to begin to understand this disease, as it is becoming an increasing threat to the well-being
of the population. Explicitly, the older population holds the most considerable risk, with the
average age of diagnosis being 60 years old (Michael J. Fox Foundation, 2019). In all, in order to
treat this threatening issue, its history and biology must be understood to determine an effective
method by which this disease can be treated.
In 1817, a man by the name of James Parkinson became the first person to define
Parkinson’s disease (Mhyre et al., 2012). Initially, it was referred to as “shaking palsy” due to the
tremors experienced (Jankovic, 2008; Mhyre et al., 2012). Altogether, Parkinson wrote An Essay
on Parkinson’s Disease in 1817, which sought to describe the disease (Obeso et al., 2017).
Throughout the rest of history, more information became known about the disease as discoveries
were continually made through various studies. For example, a discovery in the brain that has
allowed scientists to begin to understand the pathology of Parkinson’s disease is the presence of
Lewy bodies, which are intracellular protein aggregates that have been identified as a causative
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factor (Mhyre et al., 2012). Thus, as progress has been made over time, the overall perception of
why Parkinson’s disease occurs has developed.
Currently, research has attributed the cause of Parkinson’s disease to a metabolite called
3,4-dihydroxyphenylacetaldehyde, which is referred to as DOPAL (Burke et al., 2008).
Altogether, when analyzing the biology of Parkinson’s disease, DOPAL has been shown to have
a toxic effect on the brain (Burke et al., 2008). Specifically, the substantia nigra, which helps
control movement by processing feedback, is affected by DOPAL (Brown et al., 2014; Burke et
al., 2008). Thus, Lewy bodies accumulate in the substantia nigra, which causes feedback to
malfunction (Burke et al., 2008). As a result, this has led to four cardinal motor symptoms
forming as a result. The first symptom that characterizes Parkinson’s disease is a tremor, which
is often demonstrated by a shaking of the hands (Jankovic, 2008). The second symptom is
rigidity, which is the inability to complete movements without some resistance from the
contraction of the muscles within the body (Jankovic, 2008). Third, bradykinesia is a physical
trademark of Parkinson’s disease. It is typically described as slow movement, and it can be
observed by how those with Parkinson’s disease shuffle their feet when they walk (Jankovic,
2008). Last, postural deformity occurs, which is typically exemplified by the back and/or neck
being extremely flexed (Jankovic, 2008). Additionally, this can also occur in the legs, leading to
instability (Jankovic, 2008). As a result, falling can be common. Aside from motor symptoms,
non-motor symptoms also occur. These include cognitive disorders, depression, constipation,
rapid eye movement disorder, and olfactory dysfunction (Zhang et al., 2016). Altogether, the
complexity of Parkinson’s disease and its wide range of symptoms has made it difficult for
scientists to find a cure that is able to address each aspect of the disease
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Presently, no cure has been found for Parkinson’s disease. Therefore, therapeutic methods
have been introduced in order to alleviate symptoms and improve quality of life (Zhang et al.,
2016). Thus, this issue at hand provides a list of questions that need to be answered:
•

What therapies or methods are currently available that can treat the symptoms of
Parkinson’s disease?

•

In light of there being many proposals for treatment, how many are effective and what
factors of the disease does it treat?

•

For the future, what therapies may be increasingly used or introduced?

•

If possible, are there any hypotheses that are being tested in order to hopefully find a
cure?

Throughout this thesis, various types of therapies will be discussed in terms of their
effectiveness and what areas of the disease they impact. Thus, the overall quality of life for the
patient, and the severity of the disease will be discussed. Then, the future of treatment will be
considered in order to propose what specific methods will either be introduced or used more on a
routine basis. Altogether, the hopes for a cure will be discussed as well in terms of what is being
done to achieve this goal.
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Review of Literature
After conducting research throughout various databases and reading a plethora of articles,
three general categories were found that serve as a method of treatment. First, physical exercise
has been shown to be the most diverse method as it contains a multitude of routes by which one
can exercise to treat their symptoms. Second, genetics has been shown to be a route of treatment.
However, very little work has been done within this field. Third, pharmacological methods have
been utilized to reduce the symptoms of Parkinson’s disease, but side effects have been shown to
create a complicated situation. Fourth, various alternative therapies have been introduced in
order to provide treatment. Finally, as research continues, the future of treatment will progress by
either emphasizing certain treatments or introducing ideas that could lead to a cure. In all, when
addressing current treatment, each category is a different route by which various scientists have
attempted to alleviate the symptoms of Parkinson’s disease. Therefore, it is critical to understand
the impact of each category and its methods.
Physical Exercise as a Method for Treatment
Initially, when attempting to evaluate the efficacy of physical exercise, two articles were
predominantly used to determine if this route was productive and significant. First, a study by
Fabian David and Julie Robichaud (2015) was analyzed in which the cognitive factor of the
disease was assessed in relation to resistance and strengthening exercises. Overall, this article
was chosen due to its specific focus on the topic of cognitive benefits and its usage among the
scientific community with 59 total citations. Within the article, 38 patients were split into two
groups, and one participated in resistance exercises while the other took part in strengthening
exercises (David et al., 2015). Altogether, each group experienced cognitive benefits that
improved working memory and conflict resolution (David et al., 2015). However, the resistance
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group experienced improvements in selective attention as well (David et al., 2015). In all, this
article displayed that physical exercise benefits the non-motor symptoms of Parkinson’s disease.
In the second article by Franciele Cascaes da Silva and Rodrigo da Rosa Iop (2018), motor
symptoms were assessed by addressing various methods such as tango dancing and Wii-Fit.
Within the study, nine different articles were evaluated that discussed these physical exercises
and, it was found that motor symptoms did improve, as shown in specific methods such as WiiFit and treadmill training (da Silva et al., 2018). Overall, this article reinforced the concept of
utilizing physical exercise as a method of treatment as well.
Aside from the advantages of physical exercise, the disadvantages also need to be
addressed. In a study done by Terry Ellis and Jennifer Boudreau (2013), 96 patients with
idiopathic Parkinson’s disease were evaluated for why they did not consistently exercise each
week to improve their health. These participants stated that low outcome expectations, lack of
time, and fear of falling were the three primary reasons why they did not partake in physical
exercise programs (Ellis et al., 2013). Therefore, the patients explained that they did not expect
to reap any significant benefits while also believing that they did not have enough time to
exercise. Additionally, the fear of falling, which was most likely due to postural instability, was
described as limiting their motivation (Jankovic, 2008). Through this study, it can be shown that
limitations do exist within this methodology, as the symptoms of this disease decrease
motivation and belief that improvements can occur. Aside from these three limitations, an
additional barrier was also found to exist. Due to those with Parkinson’s disease typically being
older, physical degeneration must also be taken into account as a potentially limiting factor
(Michael J. Fox Foundation, 2019). Therefore, orthopedic surgery may be necessary as the hip,
knee, or spine can be damaged from prolonged constant pressure. In addition, orthopedic surgery
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has been found to be a limitation for those who want to undergo physical treatment based on a
study by Catherine C. Price and Shellie Anne T. Levy (2015). Within the study, eight patients
with Parkinson’s disease were admitted into the test (Price et al., 2015). Altogether, three of the
participants had not undergone orthopedic surgery, while the other five had undergone a
procedure (Price et al., 2015). Overall, it was found that orthopedic surgery was associated with
cognitive decline, thus labelling it as a potential factor that would inhibit treatment (Price et al.,
2015). In the end, these were the only two articles found that addressed limitations as no other
studies specifically addressed any other limitations such as lack of motivation and procedures
that may inhibit treatment.
After conducting this initial research on physical exercise as a method for treatment,
specific routes were then researched in order to examine what was offered and how effective the
procedures were. Thus, an article by Jie Dong and Yanhua Cui (2016) was selected, as it
involved a review of a multitude of physical treatment methods. Altogether, Tai Chi, dance, and
yoga were some of the main mechanisms discussed, and they were found to produce motor
benefits such as improved balance, strength, and flexibility (Dong et al., 2016). When conducting
research specifically on these methods, an article by Xiaojia Ni and Shaonan Liu (2014) was
found that addressed Tai Chi. Within the procedure, these authors analyzed Tai Chi by collecting
various articles about the subject and evaluating them to determine which ones were the most
reliable and impactful (Ni et al., 2014). Overall, it was found through the article that Tai Chi was
shown to improve mobility along with the quality of life (Ni et al., 2014). Concerning dance, an
article by Kristi Michels and Ornella M. Dubaz (2018) was found that addressed dance as a
method of treatment. In the procedure, 13 patients with Parkinson’s disease were split into
groups where only one participated in dancing for 10 weeks (Michels et al., 2018). After the
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study, the two groups were then compared in order to analyze the benefits of dancing. The
patients within the exercise group were found to improve emotionally, mentally, and physically
(Michels et al., 2018). Therefore, it was supported that dance is a potential physical method of
treatment. Finally, when addressing yoga, a study by Marieke Van Puymbroeck and Alysha A.
Walter (2018) was chosen as it specifically addressed the disease by having 30 patients with
Parkinson’s disease partake in the experiment. Within the procedure, the 30 participants were
split into a control group and yoga group. Then, an eight-week program began for the yoga
group, and at the end of the trial, the groups were compared. Altogether, it was discovered that
motor symptoms for the yoga group improved significantly in factors such as balance and
posture (Van Puymbroeck et al., 2018). In another article, the authors, Corjena Cheung and
Rozina Bhimani (2018), also tested yoga in relation to Parkinson’s disease. Within the study, 20
patients with Parkinson’s disease were chosen to undergo a 12-week program. Every week, the
patients would participate in two hour-long sessions of yoga (Cheung et al., 2018). In order to
provide results, the participants were evaluated at baseline, 12 weeks, and six months postintervention (Cheung et al., 2018). In all, motor symptoms were shown to improve in the
participants when they were examined post-intervention (Cheung et al., 2018).
When looking for other methods not mentioned by Dong and Cui, several other programs
were found. For instance, treadmill training was addressed in an article by Gammon M. Earheart
and April J. Williams (2012). Within the procedure, 203 patients were chosen that had
Parkinson’s disease with severity ranging from stages one to three based on the Hoehn & Yahr
scale (Earhart & Williams, 2012). Each participant underwent evaluations that assessed gait,
walking speed, freezing of gait, the severity of symptoms, and quality of life (Earhart &
Williams, 2012). Then, sessions on the treadmill were conducted and, evaluations were taken
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post-intervention (Earhart & Williams, 2012). Overall, each field was shown to improve, along
with no adverse events occurring (Earhart & Williams, 2012). In another study by Lisa M.
Shulman and Leslie I. Katzel (2013), treadmill training at different intensities was compared to
strength and resistance exercises. A total of 60 patients with Parkinson’s disease were tested, and
it was shown in every type of exercise that improvements in fields such as VO2 peak and
distance walking were observed (Shulman et al., 2013). In comparison to strength and resistance
exercises; however, treadmill training showed better results for VO2 peak while only strength
benefits came from the strength and resistance exercises (Shulman et al., 2013). In all, treadmill
training was verified by each study as a method of treatment for Parkinson’s disease that
specifically affected motor symptoms (Earhart & Williams, 2012; Shulman et al., 2013). Aside
from these sources, no articles were found in order to provide further data relative to treadmill
training.
Concerning another method of treatment, it was found that in an article by Alessandro
Picelli and Stefano Tamburin (2014), robot-assisted arm training was tested to evaluate if motor
improvements would occur. In total, 10 patients with idiopathic Parkinson’s disease underwent
five training sessions a week, for two weeks where a robot-assisted them in passive and active
movements of the right arm (Picelli et al., 2014). By the end of the experiment, the functionality
of the arm and hand was shown to have improved, but the quality of life showed no changes
(Picelli et al., 2014). This lack of change could have possibly been attributed to the procedure
having no long-term follow-ups (Picelli et al., 2014). In the end, if another trial were to occur,
long-term follow-ups would need to be utilized. Altogether, when looking for additional data on
robot-assisted training in relation to Parkinson’s disease, no other articles were found.
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Another trial that has been proposed is boxing training. In an article by Stephanie A.
Combs and Dyer Diehl (2011), seven male patients with Parkinson’s disease joined the program,
Rock Steady Boxing, for a total of 12 weeks. Within the program, the participants engaged in
exercises that activated the upper and lower body through activities such as punching and
shuffling of the feet (Combs et al., 2011). At the end of the experiment, improvements in
mobility, balance, and quality of life were observed (Combs et al., 2011). Overall, boxing was
shown to be a potential method of treatment, but further studies would need to be conducted that
involved females, as only males participated in the trial. When looking for further information,
no other articles were found that reinforced or debated the results of the study.
Finally, one last physical exercise that has been presented is a balance program. In a
study by David W. Sparrow and Tamara R. DeAngelis, 23 patients with idiopathic Parkinson’s
disease were separated into two groups that would each undergo a three-month balance program
and a three-month period of inactivity (Sparrow et al., 2016). Overall, balance and fear of falling
were assessed utilizing various tests such as the Falls Efficacy Scale-International and the MiniBESTest (Sparrow et al., 2016) Altogether, it was observed that improvements occurred for
each group (Sparrow et al., 2016).
Genetics as a Method for Treatment
Within the past decade, research within genetics has become a topic for addressing
Parkinson’s disease (Lin & Farrer, 2014). This is due to various experiments, such as a genomewide association study that was able to identify 11 different loci in Parkinson’s disease patients
(Lin & Farrer, 2014). Altogether, the linkage between genetic mutations and Parkinson’s disease
has been supported and led to research ventures in order to develop genetic methods of treatment
(Lin & Farrer, 2014).
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In the article by Dong and Cui (2016), gene therapy was introduced as a potential
method of treatment in order to reverse the effect of the defective genes. Methods, such as using
a vector to import a carried gene, have been tested and shown to improve the severity of
symptoms (Dong et al., 2016). In a study conducted by Raymond T. Bartus, Marc S. Weinberg,
and Richard Jude S. Samulski (2014), five different gene therapies were utilized in order to
evaluate if benefits would be reaped. First, adeno-associated viral vectors and glutamic acid
decarboxylase were used to see if motor control would improve (Bartus et al., 2014). Within the
trial, 45 subjects with Parkinson’s disease were selected with 50% undergoing treatment, while
the other half was a sham group (Bartus et al., 2014). After conducting the trial, a difference of
3.4 points was observed in the Unified Parkinson’s Disease Rating Scale based on a clinicianscored motor evaluation (Bartus et al., 2014). Despite these positive results, the clinical effects
were observed to be minimal overall. For example, five subjects were eliminated from the study
after the trials as the magnetic resonance imaging showed that the injections were off-target
(Bartus et al., 2014). Additionally, when the PDQ-39 was used to evaluate the health status of the
subjects, 21 efficacy points out of 39 were observed to show no difference before and after
treatment (Bartus et al., 2014). Overall, it was concluded that the results were shown to be
minimal and insignificant (Bartus et al., 2014).
In the second trial, adeno-associated viral vectors and aromatic L-amino acid
decarboxylase were used to enhance dopamine levels (Bartus et al., 2014). Before human trials,
1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine was used on monkeys to replicate the symptoms
of Parkinson’s disease, as this compound has been found to target the same neurons that
degenerate the brains of those with the disease (Bartus et al., 2014; Sian et al., 1999). After
conducting the trial on the primates, the process was shown to be safe and moved forward to
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human clinical trials. In the selection process, 15 humans with moderately advanced Parkinson’s
disease were chosen (Bartus et al., 2014). Due to clinical difficulties, treatment did not begin for
another year, as the program shifted companies and locations (Bartus et al., 2014). However,
after the period of waiting, two separate trials were conducted 10 years apart that both targeted
the putamen, which is a structure in the brain concerned with movement and learning (Bartus et
al., 2014; Mehrnoosh Ghandili & Sunil Munakomi, 2019). In both trials, the dosage was a topic
of debate. Concerning the putamen, one trial was shown to cover 30-40% of the structure but
only resulted in 5-6% of AADC-expressing neurons being activated (Bartus et al., 2014). Thus,
the dosage in relation to volume and density remains uncertain, and further study is still needed.
Overall though, modest results were still shown for treating symptoms (Bartus et al., 2014).
For the third trial, Lenti-aromatic L-amino acid decarboxylase along with tyrosine
hydroxylase and guanosine 5′-triphosphate cyclohydrolase1 were tested (Bartus et al., 2014).
Within the procedure, 15 subjects with Parkinson’s disease received injections to test the
effectiveness of the infusions in relation to the dosage amount (Bartus et al., 2014). Overall,
three-ascending doses were tested that each consisted of a five-fold dose range (Bartus et al.,
2014). By the end of the trials, modest improvements were observed (Bartus et al., 2014). For
example, the patients’ scores for the Unified Parkinson’s Disease Rating Scale experienced
improvements six and 12-months after the treatment started (Bartus et al., 2014). In terms of
adverse events, no severe complications occurred and were deemed unrelated to treatment
(Bartus et al., 2014). However, it was found that when L-dopa dosage was lowered, the level of
dyskinesia being experienced also lowered (Bartus et al., 2014). In the end, the treatment was
still deemed as relevant despite the complications experienced by the patients (Bartus et al.,
2014).

THE TREATMENT OF PARKINSON’S DISEASE

12

Concerning the fourth trial, adeno-associated viral vectors and neurotrophic factors were
evaluated. Within the procedure, two phase two trials were conducted that appeared to have
disappointing results in terms of improving motor abilities (Bartus et al., 2014). However, it was
shown that improvements did occur in aspects, such as quality-of-life (Bartus et al., 2014). In
order to improve this process, another protocol was conducted that introduced changes such as
increasing the dose and volume of the vector to the putamen (Bartus et al., 2014). Other changes
that occurred were that the subthalamic nucleus was targeted to a greater extent, while the blind
assessment period was extended for several months (Bartus et al., 2014). Based on trials with
animals, the hypothesis was that these changes would improve the biological responses to the
injections (Bartus et al., 2014). After conducting this phase of trials, similar results occurred as in
the initial phase two trials (Bartus et al., 2014). Thus, the methodology was reevaluated, and it
was determined that the treatment might be ineffective due to a poor therapeutic gene transport
system to the pathological brain tissue. (Bartus et al., 2014). As a result, the dosage was
increased by three- to four-fold while the volume per injection increased by 10-fold in the
putamen alone (Bartus et al., 2014). In order to ensure an active repair of neurons in the
subthalamic nucleus, a sizeable dosage was also injected into the degenerating cells of this
location (Bartus et al., 2014). By the end of this trial, significant results still did not occur (Bartus
et al., 2014). Thus, it was concluded that merely improving the blanket gene delivery coverage
may not result in improvements of symptoms (Bartus et al., 2014). In terms of other factors, the
structure of the brain was then assessed to see if possible axonal damage may have occurred
(Bartus et al., 2014). If damage did occur, then it was possible that the injection was not reaching
the putamen (Bartus et al., 2014). After conducting an autopsy of a human brain with
Parkinson’s disease and comparing it to an animal brain also diagnosed with Parkinson’s disease,
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it was observed that the neuronal pathology was more severe in the human brain (Bartus et al.,
2014). Thus, it was acknowledged that in order to produce improvements, animal models needed
to greater reflect clinical conditions (Bartus et al., 2014). As a result, this would then allow future
experiments to effectively target certain areas of the brain (Bartus et al., 2014).
Finally, adeno-associated viral vectors and glial-derived neurotrophic factors were
assessed (Bartus et al., 2014). As in the fourth trial, no significant improvements were observed
to have occurred (Bartus et al., 2014). Thus, the issue of axonal damage was also addressed
(Bartus et al., 2014). Overall, no further progress was made in the trials, as it was stated that
more information was needed in order to determine if axonal damage was a factor or not (Bartus
et al., 2014)
Altogether, when searching for further articles on gene therapy, an article by Amaal
AlDakheel and Lorraine V. Kalia (2013) discussed kinase inhibitors and α-synuclein-directed
therapies. Regarding kinase inhibitors, the target of the inhibitor would be a mutated LRKK2
gene, which is the most common genetic cause of autosomal dominant Parkinson’s disease
(AIDakheel et al., 2013). Thus, it has been hypothesized that if the toxic kinase activity of an
LRKK2 gene can be inhibited, then it can result in a disease-modifying effect (AIDakheel et al.,
2013)
Concerning the α-synuclein gene, its mutation is associated with the pathogenesis of
Parkinson’s disease due to it being responsible for the formation of Lewy bodies, which are
hallmarks of Parkinson’s disease (AIDakheel et al., 2013). Additionally, the α-synuclein
mutation has also been associated with Parkinson’s disease due to the event that its oligomers
aggregate, which leads to the most toxic forms of α-synuclein being created (AIDakheel et al.,
2013). As a result, this toxic formation can result in neuronal dysfunction and death (AIDakheel
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et al., 2013). In order to combat Parkinson’s disease, it was hypothesized that the correction of
this mutated gene would result in neuroprotection, thus inhibiting any further progression
(AIDakheel et al., 2013). In terms of addressing the issue, a vaccine route is being pursued where
antibodies would destroy the mutated gene (AIDakheel et al., 2013). For methods that have been
proposed but not pursued, a variety is available. For example, directly blocking α-synuclein
aggregation with monoclonal antibodies, short peptides, or small molecules has been proposed
(AIDakheel et al., 2013). Additionally, the promotion of chaperone function could cause αsynuclein clearance (AIDakheel et al., 2013). Finally, RNA interference technology has also
been proposed to reduce the levels of harmful proteins present (AIDakheel et al., 2013).
In all, the methods proposed were deemed likely to hold potential for treatment, but were
still in the early stages of testing and not fully confirmed as effective (AIDakheel et al., 2013).
With regards to the future, gene sequencing will need to continue in order to identify if there are
more loci associated with Parkinson’s disease (Lin & Farrer, 2014). In terms of research, no
other sources were found that directly addressed Parkinson’s disease. Therefore, these articles
were chosen as they were the only ones found that were reliable.
Pharmacological Therapies as a Method for Treatment
Another aspect of treatment for Parkinson’s Disease is the pharmacological field, which
consists of a variety of methods that have been tested in order to determine which drugs are
useful for treating various symptoms or improving motor skills. Currently, levodopa-carbidopa, a
capsule taken orally, is the first choice for symptomatic treatment (Rizek et al., 2016). It has been
shown to have a better, more controlled effect on motor symptoms in comparison to other
methods such as dopamine agonists (Rizek et al., 2016). Within a study conducted by Lin-Lin
Gao, Jia-Rong Zhang, Piu Chan, and Ta Wu, 30 patients with Parkinson’s disease were treated
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with levodopa-carbidopa to examine its effects on the basal ganglia motor circuit (Gao et al.,
2016). Regarding the basal ganglia motor circuit, it is a necessary component in the brain for
conducting motor and cognitive skills that can be affected by Parkinson’s disease by decreasing
its connectivity for neural communication (Caligiore et al., 2017; Gao et al., 2016). As a result,
this has been found to lead to bradykinesia (Gao et al., 2016). For comparison, a control group of
30 participants without Parkinson’s disease were collected and studied as well (Gao et al., 2016).
At the end of the study, levodopa-carbidopa was found to rebuild connectivity for the basal
ganglia motor circuit and other various regions of the brain, with the most significant motor
benefits being reaped on the side most affected by the disease (Gao et al., 2016). Specifically
regarding bradykinesia, its effects were also shown to be reduced (Gao et al., 2016). Altogether,
various limitations were addressed in the study that pertained to the lack of observation of other
symptoms, such as tremor and rigidity (Gao et al., 2016). No other analyses were conducted for
other antiparkinsonian medications to observe their effect on the basal ganglia motor circuit (Gao
et al., 2016). Concerning rigidity, another study was conducted by Philippe Rizek, Niraj Kumar,
and Mandar S. Jog that found that rigidity was improved with levodopa-carbidopa treatment
(Rizek et al., 2016). Within this study, levodopa-carbidopa was found to be beneficial, but
various limitations of the drug were addressed. It was observed in patients that after taking
levodopa-carbidopa treatment, dyskinesia was shown to have been inducted as a result (Rizek et
al., 2016). In another study, dystonia was also shown to be induced by levodopa-carbidopa
(Obeso et al., 2017). Due to these side effects, dopamine agonists, despite their lesser potential
for effective treatment, have been introduced as a possible initial treatment (Rizek et al., 2016).
However, it was shown that after 10 years of taking this medication, the benefits diminished and
were then equal to levodopa-carbidopa (Rizek et al., 2016).
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A variation of the levodopa-carbidopa capsule that has been introduced as a potential
method for treatment is a levodopa-carbidopa intestinal gel (Rizek et al., 2016). By utilizing
percutaneous tube insertion, the gel is injected into the jejunum continuously for 16 hours every
day (Rizek et al., 2016). In regards to safety, there is no age limit for the treatment, but it has
been recognized that those with severe dementia may be unable to retain the jejunal tube (Rizek
et al., 2016). Overall though, this method has been shown to lead to faster absorption of the
medication compared to oral levodopa-carbidopa (Rizek et al., 2016). In a seven-year-long study
of 59 patients with Parkinson’s disease, 90% stated that they experienced improvements in
quality of life and autonomy (Rizek et al., 2016). Only 19-26% reported discontinuation of the
treatment method due to reasons such as adverse drug reactions, poor compliance, lack of
efficacy, and adverse procedure/device-related events (Rizek et al., 2016). Altogether, levodopacarbidopa intestinal gel has been shown to be a viable option when considering a treatment that
utilizes levodopa-carbidopa.
Another form of pharmacological treatment that has been introduced for Parkinson’s
disease is nonsteroidal anti-inflammatory drugs (Ren et al., 2018). Due to Parkinson’s disease
partially being caused by neuroinflammation, nonsteroidal anti-inflammatory drugs have been
proposed as a method of treatment since they have been shown to eliminate inflammation of the
limbs (Ren et al., 2018). As a result, nonsteroidal anti-inflammatory drugs have been used widely
in clinical settings (Ren et al., 2018). However, there are concerns regarding the link between
liver damage and nonsteroidal anti-inflammatory drugs (Ren et al., 2018). This is primarily due
to the various chemicals present that can be toxic for the liver when processed (Bessone, 2010).
For example, salicylic acid, which is used in aspirin, can trigger mitochondrial dysfunction
(Bessone, 2010). This leads to a decrease in intracellular adenosine triphosphate, which can then
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result in lethal hepatocellular injury (Bessone, 2010). Overall, it has been reported that 10% of
the total drug-induced hepatotoxicity incidents are related to nonsteroidal inflammatory drugs
(Bessone, 2010). Altogether though, the rate of occurrence concerning these drugs and liver
damage is low, as an estimated 0.29 to 3.1 people per 100,000 exposed have been found to have
issues (Bessone, 2010). Thus, this route of treatment has been deemed safe, as it holds minimal
risk for the user (Bessone, 2010).
Regarding specific goals in relation to pharmacological treatment, a study done by Amaal
AlDakheel and Lorraine V. Kalia (2013) utilized drugs and multiple substances to focus on the
subjects of neuroprotection and disease modification. In the study, antioxidants and
mitochondrial enhancers were addressed along with dopamine agonists and L-dopa (AIDakheel
et al., 2013). Additionally, trophic factors and other methods, such as apoptosis drugs, were also
utilized (AIDakheel et al., 2013). Altogether, the results of the study were not conclusive, and it
was suggested that further studies needed to be conducted. In another study, neuroprotection and
disease modification were also addressed by using metabotropic glutamate receptors as potential
targets for neuroprotection (Masilamoni & Smith, 2018). This was due to their role in neuronal
excitability, transmitter release, and long-term synaptic plasticity (Masilamoni & Smith, 2018).
Overall, improved neuroprotective properties were obtained as a result (Masilamoni & Smith,
2018). In all, this study revealed that this methodology holds potential and requires further study
for human applications (Masilamoni & Smith, 2018).
Despite the various benefits of pharmacological treatments, a variety of side effects have
been reported for numerous drugs. First, the usage of pergoline and cabergoline, which are
ergoline dopamine agonists, have been linked to fibrotic cardiac valve damage, as demonstrated
in a study of 11,417 participants (Csoti et al., 2016). Second, pramipexole, which is another
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dopamine agonist, has been shown to lead to cardiac insufficiency (Csoti et al., 2016). Third,
dopamine agonists, along with amantadine, have been shown to cause peripheral edemas in the
ankles and legs (Csoti et al., 2016). Overall, the study of numerous patients showed a prevalence
ranging from five to 40 percent (Csoti et al., 2016). Next, it has been demonstrated that some
Parkinson’s disease medications prolong the QT interval for the beating heart (Csoti et al., 2016).
As a result, drugs, such as budipine, have been shown to cause arrhythmia (Csoti et al., 2016). A
fifth side effect that has been reported is that the frequent usage of catechol-O-methyltransferase
inhibitors have been linked to diarrhea (Csoti et al., 2016). Additionally, dopa decarboxylase
inhibitor benserazide has been observed to cause diarrhea on rare occasions (Csoti et al., 2016).
Altogether, it has also been reported that these drugs have also been shown to cause liver failure
(Csoti et al., 2016). Sixth, levodopa has been shown to influence insulin secretion, which can
possibly result in pathological glucose tolerance and insulin resistance (Csoti et al., 2016).
Pertaining to the severity of complications, various drugs have been banned as a result of
their associated complications (Rizek et al., 2016). Primarily, drugs that block dopamine
receptors have been shown to result in parkinsonism, weakened motor skills, and neuroleptic
malignant syndrome (Rizek et al., 2016). Thus, neuroleptics, antiemetics, tetrabenazine, and
antihypertensives have been removed as medications for Parkinson’s disease (Rizek et al., 2016).
Specifically concerning those receiving monoamine oxidase B inhibitors, it has been
recommended that meperidine not be taken as well, as this can lead to serotonin syndrome,
which can include fever, confusion, death, and other various symptoms (International Anesthesia
Research Society, n.d.; Rizek et al., 2016).
Finally, the usage of antiparkinsonian medications can have negative implications, as the
abrupt withdrawal of this treatment can cause akinesia and neuroleptic malignant syndrome
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(Rizek et al., 2016). Additionally, the abrupt discontinuation of dopamine agonists can cause
withdrawal symptoms (Rizek et al., 2016). Overall, various other side effects can occur, such as
levodopa-induced dyskinesia and dystonia (Obeso et al., 2017). Thus, when considering drugs
for treatment, the side effects should be taken into consideration before usage, as the benefits can
be equaled by the disadvantages.
In regards to a potential cure instead of a therapy, one particular hypothesis has been
proposed. Within this idea, it has been suggested that a drug can be created that can break down
DOPAL. Therefore, the progression of the disease will stop as a result. Currently, this hypothesis
is being tested at Southeastern University, where a research team has been conducting
experiments in order to yield DOPAL through various routes (Darby Huber et al., 2019). Overall,
the goal of the team is to send off this product to another lab in hopes that it can then be studied
to create an inhibitory drug (Darby Huber et al., 2019). Over time though, this task has been
shown to be difficult, however, as it has been observed that DOPAL quickly oxidizes (Darby
Huber et al., 2019). Thus, when DOPAL comes into contact with the atmosphere, it
automatically breaks down due to the oxygen present (Darby Huber et al., 2019). As a result,
modifications have been made by the research team to address this issue (Darby Huber et al.,
2019). Within the past year, these modifications have allowed the research team to produce a
pure yield of 20% (Darby Huber et al., 2019). In light of this success, the research team is
currently focusing its efforts to now increase this yield by improving the routes used (Darby
Huber et al., 2019). Additionally, the team is also introducing other possible routes, in hopes that
a better method may be discovered (Darby Huber et al., 2019). In all, work is still being
conducted by the research team at Southeastern University to produce higher yields so that more
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products can be sent to other labs for research to create a DOPAL-inhibiting drug (Darby Huber
et al., 2019).
Alternatives Therapies as a Method for Treatment
When searching for various therapies for treatment, a multitude of procedures were found
that did not meet the criteria of the other three categories. Therefore, they were labelled as
alternative therapies. Concerning a study by Taehun Kim and Kiho Cho (2012), herbal medicines
were addressed in relation to treating Parkinson’s disease. Within the study, 59 articles were
chosen that tested four different trials (Kim et al., 2012). First, herbal medicines, such as
Banisteriopsis caapi extract, were compared to placebo treatment. Second, herbal medicines were
compared to conventional medicines. Third, herbal medicines were combined with an active
drug and compared to the active drug being used solely. Finally, herbal medicines were
combined again with an active drug and compared to placebo treatment plus an active drug. In
all, once all the studies were completed, it was concluded that herbal medicines do not hold
potential solely as a method of treatment because of their minimal benefits for symptoms.
However, it was proposed that they may serve well as an adjunctive treatment to conventional
drugs (Kim et al., 2012). Overall, when analyzing other articles, Dong and Cui (2016) also
addressed herbal medicines within their article. Multiple benefits, such as improving
neuropsychiatric symptoms, were discussed, but no conclusive statements were given regarding
the overall effectiveness of herbal medicines (Dong et al., 2016). Concerning other articles,
multiple studies were conducted as well, but the results were not reliable. Therefore, the articles
discussed in this paragraph were deemed to be the only reliable results for discussion.
Next, an alternative method that has been proposed is deep brain stimulation. In the
article written by Dong and Cui (2016), this procedure is described as electrodes being implanted
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in the brain in order to stimulate the subthalamic nucleus and globus pallidus internus. Overall,
the goal is to dissociate both input and output information and block unusual signals through the
cortico-basal ganglia loop (Dong et al., 2016). Within the study, it was reported that through this
procedure, improvements occurred for dopaminergic neuron survival along with increased brainderived neurotrophic factor levels in the substantia nigra and primary motor cortex (Dong et al.,
2016). Altogether, it was stated that these improvements would help alleviate symptoms and
provide neuroprotection (Dong et al., 2016). In another study conducted by Esra Doğru Hüzmeli
and Atilla Yılmaz (2018), deep brain stimulation was tested in 24 patients with idiopathic
Parkinson’s disease. In all, after evaluations were conducted before and after the experiment, it
was found that motor disabilities were reduced, and quality of life improved as a result (Hüzmeli
& Yılmaz, 2018). Thus, deep brain stimulation was verified as useful for treating Parkinson’s
disease. Overall, these articles were chosen to analyze deep brain stimulation as they both
discussed the process and the multiple benefits that could be reaped through the procedure.
Finally, one last alternative method that has been proposed is stem cell therapy
(AIDakheel et al., 2013). Due to Parkinson’s disease resulting in the loss of neurons, there is
hope that cell transplantation therapy could possibly be able to restore these losses (AIDakheel et
al., 2013). For example, animal trials in the past have yielded promising results (AIDakheel et
al., 2013). Concerning human and stem cell therapy, transplants for various issues have occurred
since 1980 (AIDakheel et al., 2013). However, controlled clinical trials have yielded
insignificant results with no major improvements occurring (AIDakheel et al., 2013).
Additionally, it has also been recognized that the complexity of Parkinson’s disease may also be
an issue (AIDakheel et al., 2013). For example, it has been observed that Parkinson’s disease is
caused by a widespread multisystem nature (AIDakheel et al., 2013). Thus, if the restoration of
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dopaminergic cells was successful, the treatment may be ineffective. This is due to the most
disabling and treatment-resistant features of the disease occurring at the later stages, which
typically are less dependent on dopaminergic cells (AIDakheel et al., 2013). In the end, stem cell
therapy appears to be riddled with complexities and limitations, as human trials for various
issues have been relatively unsuccessful while Parkinson’s disease is also complex and not easily
addressable (AIDakheel et al., 2013).
Methodology
For the methodology of the thesis, a quantitative extended literature review was chosen.
Primarily, this process was selected in order that a variety of therapies could be discussed from
an objective viewpoint. Thus, this would allow no bias towards a specific treatment. Data and a
variety of sources were initially verified before being used for the thesis through methods such as
investigating the author’s credentials and the number of citations the article has. Concerning the
origin of the sources chosen, a vast majority of the articles were retrieved from Pubmed.gov,
which is a database sponsored by the U.S. National Library of Medicine and the National
Institutes of Health. The site only contains peer-reviewed articles and is utilized by scientists
around the globe for research projects and/or literature reviews. Therefore, the articles coming
from this database have been shown to be valid and containing information that is relevant and
accurate. Regarding the research at Southeastern University, the experiments being conducted
are supervised by the research professor in order that sound methodology and results are
obtained. Thus, the data collected is applicable. For the outline of the thesis, a logical order is
utilized, as the background information of the disease is presented first so that the reader can
understand the subject. Then, the various therapies are introduced in order to address the disease
and what can be done to cure or regulate it. Finally, future therapies and a conclusion are
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presented in order to hypothesize the progression of treatment and what currently needs to be
done.
Next, the topic of the thesis is finally discussed with the various therapies to treat
Parkinson’s Disease being presented. Concerning the order of the therapies evaluated, physical
exercise was chosen to be the first subject, as it is the most prevalent form of therapy currently.
Next, genetics was then discussed in order to provide a non-physical route of treatment. Then,
pharmacological therapies were addressed. Finally, alternative therapies were then discussed last,
as they are the outlier in terms of the therapeutic techniques used.
Last, the future of treating Parkinson’s Disease is discussed in light of the methods
presented along with the efforts being made to find a cure. Overall, this methodology functions
to introduce the reader to a complex topic by providing general information concerning the
disease. This is done in a logical manner that builds upon the data presented in previous sections.
Thus, the reader should be able to understand the issue and what is being done to combat it in
terms of the present and future.
Analysis of Data
Therapeutic Analysis
Presently, Parkinson’s disease has developed into a nationwide issue, as millions of
people have been found to be affected by the disease (Marras et al., 2018). Overall, the causative
agent for this disease has been attributed to Lewy bodies, which aggregate in the brain and lead
to neurodegeneration (Mhyre et al., 2012). Additionally, DOPAL works in conjunction with
Lewy bodies, specifically in the substantia nigra, to cause motor feedback malfunctioning (Burke
et al., 2008). As a result, various symptoms form, with the main four being tremors, rigidity,
bradykinesia, and postural deformity (Jankovic, 2008). Altogether, other symptoms can develop
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due to complications from the disease and therapies (Csoti et al., 2016; Price et al., 2015).
However, explicitly concerning therapies, the majority of therapies are primarily beneficial
rather than harmful.
Pertaining to physical exercises as a therapeutic method, various methods were tested and
found to improve quality of life. First, Tai Chi was utilized in an experiment and found to
improve mobility and quality of life (Dong et al., 2016). Second, dance was also tested and found
to improve the participants’ emotional, mental, and physical levels (Michels et al., 2018). Third,
30 patients with Parkinson’s disease underwent a yoga program and were able to improve their
motor abilities (Van Puymbroeck et al., 2018). Fourth, treadmill training involved two studies for
Parkinson’s disease and resulted in improvements for gait, walking, freezing of gait, the severity
of symptoms, quality of life, distance walking, and VO2 peak (Earhart & Williams, 2012;
Shulman et al., 2013). Fifth, robot-assisted arm training was tested and led to improvements in
functionality for the arm and hand (Picelli et al., 2014). Sixth, boxing was a therapeutic method
that was shown to refine mobility, balance, and quality of life (Combs et al., 2011). Finally, a
balance program was utilized and improved balance and fear of falling (Sparrow et al., 2016).
Concerning genetics, five primary therapies were tested in order to observe if the severity
of symptoms for Parkinson’s disease could be improved (Bartus et al., 2014). The first trial
involved adeno-associated viral vectors and glutamic acid decarboxylase, with 45 subjects split
between a treatment group and a sham group (Bartus et al., 2014). Overall, the treatment had
minimal results, as there was only a 3.4 point difference in the Unified Parkinson’s Disease
Rating Scale between the groups (Bartus et al., 2014). The second trial involved adenoassociated viral vectors and aromatic L-amino acid decarboxylase in enhancing dopamine levels
(Bartus et al., 2014). Altogether, two trials were conducted with modest results occurring for
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alleviating symptoms (Bartus et al., 2014). For the third trial, Lenti-aromatic L-amino acid
decarboxylase along with tyrosine hydroxylase and guanosine 5′-triphosphate cyclohydrolase1
were tested among 15 subjects with Parkinson’s disease (Bartus et al., 2014). In the end, modest
results also occurred with some minor complications (Bartus et al., 2014). Fourth, adenoassociated viral vectors and neurotrophic factors were tested in three different trials (Bartus et al.,
2014). Improvements in quality of life and motor abilities were observed, but the methodology
was reevaluated due to unsatisfactory therapeutic gene transport system to the pathological brain
tissue (Bartus et al., 2014). Thus, future studies were advised for improving mechanisms to target
the brain (Bartus et al., 2014). Finally, the fifth trial involved adeno-associated viral vectors and
glial-derived neurotrophic factors with no significant improvements occurring (Bartus et al.,
2014). Altogether, other possible therapeutic methods were discussed in other articles pertaining
to kinase inhibitors and α-synuclein-directed therapies (AIDakheel et al., 2013). In all, other
viable methods were discussed for treating Parkinson’s disease in light of its pathology
(AIDakheel et al., 2013).
Regarding pharmacological therapies, levodopa-carbidopa capsules have been shown to
have positive effects on improving the effects of Parkinson’s disease (Rizek et al., 2016).
However, dyskinesia dystonia can be induced as a result (Obeso et al., 2017; Rizek et al., 2016).
Thus, dopamine agonists have been used as a replacement (Rizek et al., 2016). Another method
of treatment that has been proposed is a levodopa-carbidopa intestinal gel, which is a variation of
the capsule (Rizek et al., 2016). Altogether, it is a relatively safe method and can result in faster
absorption with improvements in life and autonomy (Rizek et al., 2016). A third method that has
been proposed is nonsteroidal anti-inflammatory drugs, which have been shown to reduce
inflammation (Ren et al., 2018). Overall, issues have arisen concerning the possibility that these
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drugs cause Parkinson’s disease (Ren et al., 2018). However, studies have shown not to be
inaccurate (Ren et al., 2018). As a result, nonsteroidal anti-inflammatory drugs hold potential as
a method of treatment (Ren et al., 2018). Finally, neuroprotection and disease modification were
addressed by utilizing various types of drugs (AIDakheel et al., 2013; Masilamoni & Smith,
2018). Overall, varied results were obtained depending on the method of treatment, but routes,
such as using metabotropic glutamate receptors as potential targets, resulted in improved
neuroprotection (AIDakheel et al., 2013; Masilamoni & Smith, 2018). In all, the side effects of
numerous treatments have become a concern, as various symptoms or issues can arise (Csoti et
al., 2016; International Anesthesia Research Society, n.d.; Obeso et al., 2017; Rizek et al., 2016).
Thus, care must be taken when utilizing drugs, as the benefits must outweigh the disadvantages.
In all, a cure rather than a therapy is currently being researched at Southeastern University and
could hold great promise for treating the disease in the future (Darby Huber et al., 2019).
Finally, alternative therapies were tested for treating symptoms. First, neuroprotection
and disease modification were addressed by evaluating various methods such as antioxidants and
mitochondrial enhancers (AIDakheel et al., 2013). Overall, the results were inconclusive and in
need of further studies (AIDakheel et al., 2013). Herbal medicines were then evaluated by
analyzing three different methods, but all three were found to have no potential when used solely
as a method of treatment (Kim et al., 2012). However, it was stated that herbal medicines might
hold value when used in conjunction with conventional drugs (Kim et al., 2012). Deep brain
stimulation was evaluated by examining two different studies and was found to be useful as a
method for treatment (Dong et al., 2016; Hüzmeli & Yılmaz, 2018). Last, stem cell therapy was
tested and yielded insignificant results with various complexities and limitations occurring
(AIDakheel et al., 2013).
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In all, physical, genetic, pharmacological, and alternative methods for treatment have
been shown to yield benefits to various degrees. Exercise was found to contain the best chances
of success, as the multitude of therapies yielded positive benefits. For genetic therapy, benefits
were observed but were not as significant in comparison to physical therapeutic methods.
Regarding pharmacological therapies, various benefits were also observed depending on the
method used, but the numerous side effects presented complications concerning what
medications should be used. Overall though, a pharmacological cure may be found through
research hopefully. Finally, the various alternative methods addressed had a variety of results.
For example, stem cell therapy was found to be insignificant, while deep brain stimulation was
deemed effective (AIDakheel et al., 2013; Dong et al., 2016; Hüzmeli & Yılmaz, 2018). In all,
the diversity of the alternative methods section requires looking at each therapy individually, as
each proposed treatment addresses Parkinson’s disease in its own unique manner.
Future Methods
Altogether, as a treatment for Parkinson’s disease begins to progress, new methods will
be introduced, and others will become more prominent. Therefore, when examining the sources
discussed above, it can be acknowledged that some of these methods hold great potential. For
example, gene therapy provides a great opportunity as the genome is currently being studied to
discover Parkinson’s-associated mutations that can be treated to reverse the effects or stop the
pathological progression (AIDakheel et al., 2013; Lin & Farrer, 2014). Thus, if an effective
method were to be found, then gene therapy may be widely used for treatment. Concerning
pharmacological therapy, future research may yield different drugs that prevent Parkinson’s
disease or reduce the symptoms without causing severe side effects. Thus, therapies, such as
nonsteroidal anti-inflammatory drugs, may hold potential for the future (Ren et al., 2018).
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Another therapy that may increase in usage is robot assistance, as it has been demonstrated to
improve the functionality of the hand and arm (Picelli et al., 2014). In all, when addressing the
research being conducted at Southeastern University, additional routes are being examined to
determine if other options may hold potential for yielding higher amounts of DOPAL (Darby
Huber et al., 2019). As a result, the timeline for finding a cure has been extended, as various
options are now being evaluated (Darby Huber et al., 2019). However, this possibly provides a
higher chance of finding a cure, as more options will be available for synthesizing DOPAL
(Darby Huber et al., 2019).
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Conclusion
In all, a thorough review of literature has been conducted in order to assess the variety of
treatments that are available for treating Parkinson’s disease. Physical exercise, gene therapy,
pharmacological therapy, and alternative methods were the primary treatments evaluated and
each type was found to have numerous benefits. In the end, these assessments promoted a
discussion of the future, as certain procedures may increase in usage. A hypothesis was also
formulated in terms of addressing a possible new method that could provide a cure. Therefore,
when evaluating this thesis, numerous approaches can be utilized to provide an understanding of
what Parkinson’s disease is and what can be done to treat it.
When addressing the future for this current study, the next step that needs to be taken is
to conduct further research on the methods addressed above. For example, further investigation
needs to occur for gene therapy, as no other potential sources have been found so far. Thus, the
primary goal for the future should be directed towards reinforcing the methods that have already
been introduced. In terms of finding new methods, further research will also need to be
conducted to discover if more opportunities are available for treatment. In all, as this process
continues, more of the details for each study will be expounded upon, as the steps for each
experiment will be discussed along with the specific results. As a result, the study will continue
to be up-to-date and able to provide current information on the progress being made towards the
treatment of Parkinson’s disease.
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